C 6H8BrN3O2, monoclinic, P121/a1 (no. 14), a = 6.3952(2) Å, b = 11.1267(3) Å, c = 12.0785(4) Å, b = 97.274(2)°, V = 852.6 Å 3 , Z = 4, Rgt(F) = 0.047,
Discussion
Nitroimidazole derivatives are extensively used in the treatment of anaerobic infections and more recently as anti-Helicobacter pylori agents. They are largely studied by electrochemical methods due to the great importance of the redox potential for the understanding of the mechanism of biological activity [2] . The title compound shows significant activity against metronidazole-resistant Helicobacter pylori [3] . In the crystal structure, the imidazole ring is a well defined plane with an average deviation of 0.006 Å. The nitro N atom lies 0.057(3) Å below the plane. The two other groups attached to the ring are located on the opposite side of the plane, with deviations of C9 and C5 atoms from the best plane of 0.011(4) Å and 0.102(3) Å, respectively. 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole (metronidazole) [4] crystallizes non-isotypically because of the stronger intermolecular OH···O bonds and only weaker CH···Br interactions formed in the title structure (apart from NO···HC interactions appearing in both structures). 
